Glioblastoma (GBM) is the most common malignant primary brain tumor of adults and one of the most lethal of all cancers. New therapeutic approaches are needed. Genomic, proteomic and mouse model studies implicate mTOR kinase as a compelling GBM target. The role of mTOR complex 1 in GBM is well recognized;the role of mTOR complex 2 is poorly understood. We present exciting preliminary data demonstrating a critical role for mTORC2 signaling in GBM in promoting therapeutic resistance to rapamycin and demonstrate that inhibition of both mTOR complexes is needed to potently induce GBM tumor cell death. This proposal brings together a highly experienced collaborative team with expertise in GBM signal transduction, mTORC2 biochemistry and GBM in vitro and in vivo models to illuminate the molecular circuitry of mTOR signaling in GBM and to develop and test a novel mTOR kinase inhibitor that inhibits both mTOR signaling complexes. We will apply novel mTOR biochemical assays to genetically defined GBM in vitro and in vivo models and meticulously characterized clinical samples to illuminate the molecular circuitry and functional importance of mTORC2 signaling in GBM. In partnership with Celgene, we will develop and test a novel mTOR kinase inhibitor with potent anti-mTORC1 and mTORC2 activity We will: 1) directly measure mTORC2 activity in genetically defined GBM models and clinical samples and identify upstream activators and downstream effectors of mTORC2;2) determine whether combined inhibition of both mTOR signaling complexes is required to block tumor growth and 3) determine the efficacy of the novel mTOR kinase inhibitor for treatment of GBM patients including identifying patients most likely to benefit from the drug.
The proposed studies challenge current research and clinical practice assumptions about mTOR as a GBM target. They address a major gap in our understanding of mTOR signaling and create a pathway to translation through development and testing of a novel mTOR kinase inhibitor. We anticipate that the results obtained from this proposal will have significant impact on the treatment of GBM patients.
|Nguyen, Nam-Phuong D; Deshpande, Viraj; Luebeck, Jens et al. (2018) ViFi: accurate detection of viral integration and mRNA fusion reveals indiscriminate and unregulated transcription in proximal genomic regions in cervical cancer. Nucleic Acids Res 46:3309-3325|
|Bi, Junfeng; Wu, Sihan; Zhang, Wenjing et al. (2018) Targeting cancer's metabolic co-dependencies: A landscape shaped by genotype and tissue context. Biochim Biophys Acta Rev Cancer 1870:76-87|
|Liu, Feng; Mischel, Paul S (2018) Targeting epidermal growth factor receptor co-dependent signaling pathways in glioblastoma. Wiley Interdiscip Rev Syst Biol Med 10:|
|Gu, Yuchao; Albuquerque, Claudio P; Braas, Daniel et al. (2017) mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT. Mol Cell 67:128-138.e7|
|Turner, Kristen M; Deshpande, Viraj; Beyter, Doruk et al. (2017) Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature 543:122-125|
|Mai, Wilson X; Gosa, Laura; Daniels, Veerle W et al. (2017) Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma. Nat Med 23:1342-1351|
|Liu, Feng; Mischel, Paul S; Cavenee, Webster K (2017) Precision cancer therapy is impacted by oncogene-dependent epigenome remodeling. NPJ Precis Oncol 1:1|
|Zanca, Ciro; Villa, Genaro R; Benitez, Jorge A et al. (2017) Glioblastoma cellular cross-talk converges on NF-?B to attenuate EGFR inhibitor sensitivity. Genes Dev 31:1212-1227|
|Cosset, Érika; Ilmjärv, Sten; Dutoit, Valérie et al. (2017) Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. Cancer Cell 32:856-868.e5|
|Villa, Genaro R; Hulce, Jonathan J; Zanca, Ciro et al. (2016) An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell 30:683-693|
Showing the most recent 10 out of 41 publications